Results 151 to 160 of about 737 (195)
Some of the next articles are maybe not open access.
Experimental Dermatology, 2007
Abstract: Although introduced more than 50 years ago, topical glucocorticoids are still the first line therapy for many inflammatory skin disorders such as atopic eczema, contact dermatitis and many others. Recently, significant improvements have been made to optimize the ratio of desired to unwanted effects.
Parham, Mirshahpanah +6 more
openaire +2 more sources
Abstract: Although introduced more than 50 years ago, topical glucocorticoids are still the first line therapy for many inflammatory skin disorders such as atopic eczema, contact dermatitis and many others. Recently, significant improvements have been made to optimize the ratio of desired to unwanted effects.
Parham, Mirshahpanah +6 more
openaire +2 more sources
Overview of clinical experience with methylprednisolone aceponate
Journal of the European Academy of Dermatology and Venereology, 1994AbstractMethylprednisolone aceponate is a new potent topical corticosteroid. Chemically it is a corticoid diester that rapidly penetrates the skin. It is rapidly metabolised and then conjugated so that although potent, it does not appear to cause serious local or systemic side effects.
openaire +1 more source
Long‐term treatment with 6α‐methylprednisolone aceponate
Journal of the European Academy of Dermatology and Venereology, 1994AbstractAim 6α‐Methylprednisolone aceponate (MPA) is a new steroid double ester for topical use, the potent action and lack of untoward side‐effects of which became evident in two different studies.Background Recent studies have proved the concept that MPA is both potent and extremely well tolerated when used for a relatively short time.Methods Two ...
openaire +1 more source
Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema
Journal of the European Academy of Dermatology and Venereology, 1994AbstractMethylprednisolone aceponate (MPA) is a new topical corticosteroid developed specifically for the treatment of eczematous disorders. A multicentre, controlled, randomized open trial to assess the efficacy and tolerability of a once daily application of MPA in comparison to a twice‐daily application of Prednicarbate (PC) was conducted in 566 ...
openaire +1 more source
Skin Pharmacology and Physiology, 1997
<i>Background: </i>Topical corticoids decrease de novo collagen synthesis in the human skin. <i>Objective: </i>We studied the effect of three corticoids, hydrocortisone (HC), methylprednisolone aceponate (MPA) and momethasone furoate (MMF) on the de novo synthesis of type I and III collagens.
K M, Haapasaari +3 more
openaire +2 more sources
<i>Background: </i>Topical corticoids decrease de novo collagen synthesis in the human skin. <i>Objective: </i>We studied the effect of three corticoids, hydrocortisone (HC), methylprednisolone aceponate (MPA) and momethasone furoate (MMF) on the de novo synthesis of type I and III collagens.
K M, Haapasaari +3 more
openaire +2 more sources
Journal of the European Academy of Dermatology and Venereology, 2011
AbstractAlthough emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate‐to‐severe symptoms require treatment with anti‐inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs).
openaire +2 more sources
AbstractAlthough emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate‐to‐severe symptoms require treatment with anti‐inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs).
openaire +2 more sources
Local tolerability of topically applied methylprednisolone aceponate
Journal of the American Academy of Dermatology, 1993A, Kecskés, P, Jahn, L, Lange
openaire +2 more sources